<DOC>
	<DOC>NCT00149136</DOC>
	<brief_summary>ALL patients aged 55 years or older were treated with steroids during one week and Ph+ve cases were then offered a specific therapy including an induction treatment with steroids, cyclophosphamide, daunorubicin and vincristine, followed, irrespective of response to induction chemotherapy, by imatinib, 600 mg daily, combined with intermittent steroids during 2 months. Patients in complete response (CR) were then given 10 blocks of alternating chemotherapy, including 2 additional two-month blocks of imatinib, for a total treatment duration of 2 years. Therapy of occult central nervous system leukemia included 5 intrathecal injections of methotrexate and cranial irradiation. Duration of therapy : 2 years.</brief_summary>
	<brief_title>Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Ph+ ALL patients 55 years or older Signed written informed consent CML in transformation Concomitant malignancy Previous treatment by Imatinib Severe organ condition</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Acute Lymphocytic Leukemia,</keyword>
	<keyword>Ph+,</keyword>
	<keyword>elderly patients,</keyword>
	<keyword>Imatinib</keyword>
</DOC>